FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149258023> ?p ?o ?g. }

• W2149258023 endingPage "459" @default.
• W2149258023 startingPage "447" @default.
• W2149258023 abstract "The empirical treatment of febrile, neutropenic patients with cancer requires antibacterial regimens active against both gram-positive and gram-negative pathogens. This study was performed to demonstrate the noninferiority of monotherapy with piperacillin-tazobactam, compared with cefepime.We conducted a randomized-controlled, open-label, multicenter clinical trial among high-risk patients from 34 university-affiliated tertiary care medical centers in the United States, Canada, and Australia who were undergoing treatment for leukemia or hematopoietic stem cell transplantation and were hospitalized for empirical treatment of febrile neutropenic episodes. Patients received piperacillin-tazobactam (4.5 g every 6 h) or cefepime (2 g every 8 h) intravenously. The primary outcome was success (defined by defervescence without treatment modification) at 72 h of treatment, end of treatment, and test of cure in the modified intent-to-treat analysis. Secondary outcomes included time to defervescence, microbiological efficacy, the additional use of glycopeptide antibiotics, emergence of resistant bacteria, and safety.For 528 subjects (265 received piperacillin-tazobactam and 263 received cefepime), success rates were 57.7% and 48.3%, respectively (P = .04) at the 72-h time point, 39.6% and 31.6% (P = .06) at end of treatment, and 26.8% and 20.5% (P = .11) at the test-of-cure visit. The analyses demonstrated noninferiority for piperacillin-tazobactam at all time points (P< or = .0001). Treatment with piperacillin-tazobactam was independently associated with treatment success in multivariate analysis (odds ratio, 1.65; 95% confidence interval, 1.04-2.64; P = .035). Both regimens were well tolerated.This study demonstrates the noninferiority and safety of piperacillin-tazobactam monotherapy, compared with cefepime, for the empirical treatment of high-risk febrile neutropenic patients with cancer." @default.
• W2149258023 created "2016-06-24" @default.
• W2149258023 creator A5002514817 @default.
• W2149258023 creator A5008447743 @default.
• W2149258023 creator A5010031219 @default.
• W2149258023 creator A5025535129 @default.
• W2149258023 creator A5031643718 @default.
• W2149258023 creator A5042310258 @default.
• W2149258023 creator A5045077426 @default.
• W2149258023 creator A5061107241 @default.
• W2149258023 creator A5067136940 @default.
• W2149258023 date "2006-08-15" @default.
• W2149258023 modified "2023-10-15" @default.
• W2149258023 title "A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies" @default.
• W2149258023 cites W1571178250 @default.
• W2149258023 cites W1585569404 @default.
• W2149258023 cites W1605369936 @default.
• W2149258023 cites W1782392722 @default.
• W2149258023 cites W1898379105 @default.
• W2149258023 cites W1965039837 @default.
• W2149258023 cites W1965867548 @default.
• W2149258023 cites W1974640328 @default.
• W2149258023 cites W1977990531 @default.
• W2149258023 cites W1984864482 @default.
• W2149258023 cites W1991904626 @default.
• W2149258023 cites W1997219936 @default.
• W2149258023 cites W2004008520 @default.
• W2149258023 cites W2004392930 @default.
• W2149258023 cites W2016285998 @default.
• W2149258023 cites W2018771059 @default.
• W2149258023 cites W2041613596 @default.
• W2149258023 cites W2045490896 @default.
• W2149258023 cites W2054292547 @default.
• W2149258023 cites W2061194988 @default.
• W2149258023 cites W2062860160 @default.
• W2149258023 cites W2068871984 @default.
• W2149258023 cites W2097341466 @default.
• W2149258023 cites W2098505845 @default.
• W2149258023 cites W2099694200 @default.
• W2149258023 cites W2102237290 @default.
• W2149258023 cites W2104013660 @default.
• W2149258023 cites W2105872767 @default.
• W2149258023 cites W2108818954 @default.
• W2149258023 cites W2111723930 @default.
• W2149258023 cites W2112210977 @default.
• W2149258023 cites W2112555864 @default.
• W2149258023 cites W2113426366 @default.
• W2149258023 cites W2122014609 @default.
• W2149258023 cites W2122335736 @default.
• W2149258023 cites W2122383241 @default.
• W2149258023 cites W2122896212 @default.
• W2149258023 cites W2139805912 @default.
• W2149258023 cites W2141088505 @default.
• W2149258023 cites W2143769596 @default.
• W2149258023 cites W2145457599 @default.
• W2149258023 cites W2150741204 @default.
• W2149258023 cites W2151265719 @default.
• W2149258023 cites W2152240392 @default.
• W2149258023 cites W2157527647 @default.
• W2149258023 cites W2160374023 @default.
• W2149258023 cites W2161554499 @default.
• W2149258023 cites W2166858780 @default.
• W2149258023 cites W2166895354 @default.
• W2149258023 cites W2217407321 @default.
• W2149258023 cites W2226490553 @default.
• W2149258023 cites W2258823846 @default.
• W2149258023 cites W2268762194 @default.
• W2149258023 cites W2295631180 @default.
• W2149258023 cites W2335721167 @default.
• W2149258023 cites W4235146847 @default.
• W2149258023 cites W61016837 @default.
• W2149258023 cites W86113140 @default.
• W2149258023 doi "https://doi.org/10.1086/505393" @default.
• W2149258023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16838234" @default.
• W2149258023 hasPublicationYear "2006" @default.
• W2149258023 type Work @default.
• W2149258023 sameAs 2149258023 @default.
• W2149258023 citedByCount "104" @default.
• W2149258023 countsByYear W21492580232012 @default.
• W2149258023 countsByYear W21492580232013 @default.
• W2149258023 countsByYear W21492580232014 @default.
• W2149258023 countsByYear W21492580232015 @default.
• W2149258023 countsByYear W21492580232016 @default.
• W2149258023 countsByYear W21492580232017 @default.
• W2149258023 countsByYear W21492580232018 @default.
• W2149258023 countsByYear W21492580232019 @default.
• W2149258023 countsByYear W21492580232020 @default.
• W2149258023 countsByYear W21492580232021 @default.
• W2149258023 countsByYear W21492580232022 @default.
• W2149258023 countsByYear W21492580232023 @default.
• W2149258023 crossrefType "journal-article" @default.
• W2149258023 hasAuthorship W2149258023A5002514817 @default.
• W2149258023 hasAuthorship W2149258023A5008447743 @default.
• W2149258023 hasAuthorship W2149258023A5010031219 @default.
• W2149258023 hasAuthorship W2149258023A5025535129 @default.
• W2149258023 hasAuthorship W2149258023A5031643718 @default.
• W2149258023 hasAuthorship W2149258023A5042310258 @default.
• W2149258023 hasAuthorship W2149258023A5045077426 @default.

• next